MrMed Expands National Footprint, Plans Entry into Allied Super-Specialty Healthcare Services
Chennai: MrMed, a direct-to-patient platform focused on critical care and super-specialty medicines, has announced a new phase of expansion aimed at strengthening infrastructure, enhancing cold-chain capabilities, and widening its presence across India.
As part of its growth strategy, the company has established on-ground operations in Guwahati, adding to its existing presence in Chennai, Delhi, and Bengaluru. The expansion is intended to improve last-mile access and accelerate fulfilment timelines for patients requiring critical and temperature-sensitive medicines.
MrMed has also launched an offline cold-chain storage facility in Bengaluru to support faster delivery and improved patient access across Karnataka and the broader South India region. Chennai will continue to function as the company’s central operations and pharmacy hub. The company said it plans to further expand physical infrastructure into additional cities to strengthen nationwide delivery capabilities.
“Access to critical care medicines should not be determined by a patient’s location,” said Devashish Singh, Co-founder and CEO, MrMed, noting that the company is focused on building reliable systems to improve access to super-specialty therapies across regions.
In addition to medicine delivery, MrMed is planning to expand into allied super-specialty healthcare services. Proposed offerings include home-based cancer care services such as nurse-led infusions and pre- and post-chemotherapy support, aimed at reducing hospital visits and improving continuity of care for patients undergoing long treatment cycles.
“Long treatment cycles, particularly in oncology, require sustained care beyond hospitals,” said Saurab Jain, Co-founder, MrMed, highlighting the company’s plans to support patients through expanded home-based services.
MrMed provides access to medicines for a range of complex conditions including cancer, HIV, hepatitis, rare diseases, and other critical therapies that often require specialised storage and regulatory compliance. The company sources medicines through authorised distributors associated with major global and Indian pharmaceutical firms, including Eli Lilly, Novo Nordisk, Cipla, Dr Reddy’s, and Mankind.
